Content about Uric acid

March 18, 2013

Perrigo announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets.

ALLEGAN, Mich. — Perrigo on Monday announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets. 

April 12, 2012

Perrigo on Thursday announced that it has initiated shipments of its guaifenesin extended-release tablets in the 600-mg strength, a generic version of Mucinex.

ALLEGAN, Mich. — Perrigo on Thursday announced that it has initiated shipments of its guaifenesin extended-release tablets in the 600-mg strength, a generic version of Mucinex.

The company expects to initiate its full-scale over-the-counter launch of the store-brand equivalent to Mucinex in blister packaging to its retail and wholesale customers before the end of its current fiscal year in June.

Mucinex 600-mg tablets has estimated annual sales of approximately $135 million, according to Perrigo.

April 11, 2012

Takeda Pharmaceutical will acquire privately owned drug maker URL Pharma for $800 million, the companies said Wednesday.

DEERFIELD, Ill. — Takeda Pharmaceutical will acquire privately owned drug maker URL Pharma for $800 million, the companies said Wednesday.

Takeda announced that it would acquire Philadelphia-based URL through a U.S. subsidiary for the upfront payment plus future milestone payments. Takeda said it expected the acquisition to contribute "significantly" to its sales and profits starting in fiscal year 2013.

January 25, 2012

Help Remedies last week launched a new product targeted toward those suffering from chest congestion.

NEW YORK — Help Remedies last week launched a new product targeted toward those suffering from chest congestion. The new expectorant, branded "Help I have chest congestion," contains the single active ingredient guaifenesin (200 mg), and is now available nationally at Target, the company stated.

November 4, 2011

A consumer’s internal alarm bell usually is tripped when a company tries to sell him or her on a “less-is-more” proposition, because it usually really means “less-is-less.” That is until Help Remedies came along with its “less-is-less-but-that’s-better” proposition.


NEW YORK — A consumer’s internal alarm bell usually is tripped when a company tries to sell him or her on a “less-is-more” proposition, because it usually really means “less-is-less.” That is until Help Remedies came along with its “less-is-less-but-that’s-better” proposition.


It’s a minimalist movement of single-ingredient OTCs — less drugs, less dyes, less coatings and less confusion because all products are named “Help I have ...” followed by the one symptom treated.


August 17, 2011

Patients with gout taking a drug made by Savient Pharmaceuticals experienced "significant" improvements, according to results of two late-stage clinical trials published in the Journal of the American Medical Association.

EAST BRUNSWICK, N.J. — Patients with gout taking a drug made by Savient Pharmaceuticals experienced "significant" improvements, according to results of two late-stage clinical trials published in the Journal of the American Medical Association.

February 25, 2011

Savient said its newest drug is the first and only therapy available to treat chronic gout in adult patients refractory to conventional therapy.

EAST BRUNSWICK, N.J. — Savient said its newest drug is the first and only therapy available to treat chronic gout in adult patients refractory to conventional therapy.

The drug maker announced the U.S. commercial launch of Krystexxa (pegloticase).

February 17, 2011

Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

EAST BRUNSWICK, N.J. — Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

The drug maker appointed Louis Ferrari as its SVP corporate development, Christine Mikail as SVP and Stephen Davies as chief information officer and group VP.

February 10, 2011

Over-the-counter generic versions of a line of products used to treat congestion do not infringe on the patents covering the branded versions, a federal court ruled Wednesday.

MORRISTOWN, N.J. — Over-the-counter generic versions of a line of products used to treat congestion do not infringe on the patents covering the branded versions, a federal court ruled Wednesday.

December 10, 2010

Biotech drugs will help drive the markets for acute and chronic gout through 2019, according to a new report by market research firm Decision Resources.

BURLINGTON, Mass. — Biotech drugs will help drive the markets for acute and chronic gout through 2019, according to a new report by market research firm Decision Resources.

The report, titled “Acute and Chronic Gout — New Agents Target Refractory Patients and Tap Market Opportunity,” found that the acute gout drug market would triple in size to $117 million, while the chronic gout market would reach $1.83 billion.

December 1, 2010

Drug maker Savient Pharmaceuticals has begun shipping its new gout treatment to specialty distributors, the company said Tuesday.

EAST BRUNSWICK — Drug maker Savient Pharmaceuticals has begun shipping its new gout treatment to specialty distributors, the company said Tuesday.

Savient announced the shipment of Krystexxa (pegloticase), saying it would become available by prescription starting Wednesday.

The drug, designed for administration by IV, received approval on Sept. 14 from the Food and Drug Administration for treating chronic gout.

November 4, 2010

Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors...

EAST BRUNSWICK, N.J. Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors at the end of this month, Savient said.

The company announced that it would begin shipping Krystexxa (pegloticase) on Nov. 30, and it would become available for prescription on Dec. 1.

September 14, 2010

The Food and Drug Administration has approved a new treatment for gout, a painful condition...

WASHINGTON The Food and Drug Administration has approved a new treatment for gout, a painful condition that affects 3 million adults in the United States.

The FDA announced the approval of Savient Pharmaceuticals’ Krystexxa (pegloticase), a biotech drug for people who have not responded to or tolerated conventional therapies.

February 7, 2010

New research published in the Annals of the Rheumatic Diseases indicate that women with a...

December 20, 2009

Consumers can be expected to self-identify a cough, and even locate a cough remedy in...

NEW YORK Consumers can be expected to self-identify a cough, and even locate a cough remedy in the nonprescription aisles. But consumers cannot be expected to distinguish between dextromethorphan and guaifenesin necessarily. Both are indicated for cough relief, but work in entirely different ways. For that you need a readily accessible healthcare professional, such as the pharmacist or nurse practitioner.